Gene expression markers of Tumor Infiltrating Leukocytes

BackgroundAssays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the intratumoral abundance of various immune cell populations with gene expression. In contrast to IHC and flow cytometry, gene expression assays yield high information content from a clinically practical workflow. Previous studies of gene expression in purified immune cells have reported hundreds of genes showing enrichment in a single cell type, but the utility of these genes in tumor samples is unknown. We use co-expression patterns in large tumor gene expression datasets to evaluate previously reported candidate cell type marker genes lists, eliminate numerous false positives and identify a subset of high confidence marker genes.MethodsUsing a novel statistical tool, we use co-expression patterns in 9986 samples from The Cancer Genome Atlas (TCGA) to evaluate previously reported cell type marker genes. We compare immune cell scores derived from these genes to measurements from flow cytometry and immunohistochemistry. We characterize the reproducibility of our cell scores in replicate runs of RNA extracted from FFPE tumor tissue.ResultsWe identify a list of 60 marker genes whose expression levels measure 14 immune cell populations. Cell type scores calculated from these genes are concordant with flow cytometry and IHC readings, show high reproducibility in replicate RNA samples from FFPE tissue and enable detailed analyses of the anti-tumor immune response in TCGA. In an immunotherapy dataset, they separate responders and non-responders early on therapy and provide an intricate picture of the effects of checkpoint inhibition. Most genes previously reported to be enriched in a single cell type have co-expression patterns inconsistent with cell type specificity.ConclusionsDue to their concise gene set, computational simplicity and utility in tumor samples, these cell type gene signatures may be useful in future discovery research and clinical trials to understand how tumors and therapeutic intervention shape the immune response.

[1]  E John Wherry,et al.  T cell exhaustion , 2011 .

[2]  H. Muller-Hermelink,et al.  The serine protease granzyme M is preferentially expressed in NK-cell, gamma delta T-cell, and intestinal T-cell lymphomas: evidence of origin from lymphocytes involved in innate immunity. , 2003, Blood.

[3]  Burton E. Barnett,et al.  Cutting Edge: B Cell–Intrinsic T-bet Expression Is Required To Control Chronic Viral Infection , 2016, The Journal of Immunology.

[4]  P. Klenerman,et al.  CD39 Expression Identifies Terminally Exhausted CD8+ T Cells , 2015, PLoS pathogens.

[5]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[6]  J. Schlom,et al.  Tumor-infiltrating immune cells and prognosis: the potential link between conventional cancer therapy and immunity , 2011, Experimental biology and medicine.

[7]  Dimitris Anastassiou,et al.  Biomolecular Events in Cancer Revealed by Attractor Metagenes , 2012, PLoS Comput. Biol..

[8]  C. Sander,et al.  The landscape of T cell infiltration in human cancer and its association with antigen presenting gene expression , 2015, bioRxiv.

[9]  Z. Trajanoski,et al.  Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.

[10]  N. K. Sah,et al.  Structural, functional and therapeutic biology of survivin. , 2006, Cancer letters.

[11]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[12]  Jing Zhu,et al.  Apparently low reproducibility of true differential expression discoveries in microarray studies , 2008, Bioinform..

[13]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Jérôme Galon,et al.  The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. , 2013, Immunity.

[15]  E. Wherry,et al.  Molecular signature of CD8+ T cell exhaustion during chronic viral infection. , 2007, Immunity.

[16]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[17]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[18]  H. Masai,et al.  Functions of mammalian Cdc7 kinase in initiation/monitoring of DNA replication and development. , 2003, Mutation research.

[19]  P. Hugenholtz Exploring prokaryotic diversity in the genomic era , 2002, Genome Biology.

[20]  Pornpimol Charoentong,et al.  Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy , 2015, Genome Biology.

[21]  L. Chin,et al.  Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.

[22]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[23]  Homin K. Lee,et al.  Coexpression analysis of human genes across many microarray data sets. , 2004, Genome research.

[24]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[25]  Ash A. Alizadeh,et al.  Robust enumeration of cell subsets from tissue expression profiles , 2015, Nature Methods.

[26]  R. Geha,et al.  Adapter proteins SLP-76 and BLNK both are expressed by murine macrophages and are linked to signaling via Fcgamma receptors I and II/III. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. Parmigiani,et al.  A statistical framework for expression‐based molecular classification in cancer , 2002 .

[28]  Xiangshan Zhao,et al.  Mitosin/CENP-F in mitosis, transcriptional control, and differentiation. , 2006, Journal of biomedical science.

[29]  J. Reiffers,et al.  Expression of Flt3-ligand by the endothelial cell , 2000, Leukemia.

[30]  Ash A. Alizadeh,et al.  Abstract PR09: The prognostic landscape of genes and infiltrating immune cells across human cancers , 2015 .

[31]  D. Chaussabel,et al.  The Relationship of Immune Cell Signatures to Patient Survival Varies within and between Tumor Types , 2015, PloS one.